AstraZeneca’s Movantik Looks Clear After FDA Panel; Salix’ Relistor Looks Cloudy
Executive Summary
Naloxegol development program included long-term controlled trial, the advisory committee’s preferred approach for studying CV events with peripherally active mu opioid receptor antagonists for opioid-induced constipation, while methylnaltrexone may suffer from the lack of control arm in its long-term study.